Renal Biobank and TARGET-KD

Summary

The TARGET-KD program (The Application of Renal Genomics to Enhance the Treatment of Kidney Disease) is seeking to recruit subjects who are scheduled to undergo a kidney biopsy in the near future who are willing to donate a one-time urine and blood sample to the kidney disease biobank at the University of Calgary. Samples will be de-identified and used in future studies in order to discover and validate disease-classifying molecular and genetic indicators that may exist in the blood and urine. These discoveries could lead to the development of simple urine or blood-based diagnostic tests rather than requiring an invasive kidney biopsy to diagnose patients and treat them appropriately. We are also actively recruiting healthy volunteers without kidney disease to donate urine and blood samples on a one-time basis to be used as controls for comparison studies.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 0 to 100

Accepts healthy participants: Yes

Inclusion criteria:

Kidney disease patients:
a. Undergoing kidney biopsy procedure in Calgary
b. Patient or guardian (for patients <18 years of age) able to provide consent, medical information


Healthy Volunteers:
a. > 18 years of age
b. Willing to complete a 10-15 minute study visit at the University of Calgary
c. Willing to disclose smoking status, prior medical complications, medications
d. Can provide Alberta Provincial health card number

Exclusion criteria:

Kidney disease patients:
a. Unable to consent, fully disclose medical information

Healthy Volunteers:
a. < 18 years of age
b. Any systemic or chronic disease history
c. Unable to fully disclose smoking status, prior medical complications, medications

Participate

Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

If you would like to learn more, please visit https://www.target-kd.com or contact Graciela Andonegui at 403-210-7097 or andonegu@ucalgary.ca

Principal investigator:

Daniel Abraham Muruve

Clinical trial:

No

REB-ID:

REB17-0639

External links

TARGET-KD Website